In this study, we demonstrated not only the antiproliferative effects of targeting PHF19 in myeloid leukemias but also how its reduction leads to specific differentiation of CML cells toward the erythroid pathway. This evidence concerns the gene PHF19 and chronic myelogenous leukemia, BCR-ABL1 positive.